Verificando…
Traducido automáticamente. Dosis y advertencias: consulta el original en inglés. Leer en inglés

Cobas Pulse

NAFDAC Reg. No. A3-101048 Estupefaciente

Registrado en NAFDAC. Registro activoAs of 3 November 2026 · synced automatically from official sources.
Producto
Cobas Pulse
Número NAFDAC
A3-101048
Principio activo
Diagnostic Instrument
Dosis
NA
Forma
NA
Tamaño del envase
1 unit per pack
Fabricante
No Constan
Solicitante (titular)
Roche Products Limited
Approved
29 Sep 2023
Estado
Activo Ver en NAFDAC ↗
Registro válido hasta
28 Sep 2028
Alertas de la OMS
No se ha encontrado ninguno
Informes de la comunidad
Ninguno
Tiempos comprobados
0

Pero sobre el medicamento, Diagnostic instrument: uses, dosage and brands worldwide

Lo que encontramos

  • Cobas Pulse is on the NAFDAC register with an active registration (A3-101048). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generado automáticamente a partir del registro NAFDAC, QUIÉN alerta y los datos de la comunidad a partir de hoy. Este no es un consejo médico. Siga siempre a su médico o farmacéutico.

How to use Cobas Pulse

Lo que dice el prospecto oficial. Si te lo recetó un médico, sigue la receta. Si el prospecto de tu caja es distinto, manda el de tu caja.

Para quién es

Sodium Iodide I 131 Capsules Diagnostic is indicated for use in adults for: Assessment of thyroid function using radioactive iodine (RAI) uptake test Imaging the thyroid (scintigraphy) Sodium Iodide I 131 Capsules Diagnostic is a radioactive diagnostic agent indicated for the assessment of thyroid function and for thyroid imaging.

Cómo tomarlo y con qué frecuencia
  • Use careful handling with appropriate safety measures to minimize radiation exposure to patients and healthcare workers
  • Follow suitable radioactivity calibration prior to administration
  • In an adult patient, recommended doses are : Thyroid Function: 0.185 to 1.1 megabecquerels (MBq) [5 to 30 microcuries (microCi)] Thyroid Imaging: 1.85 to 3.70 MBq (50 to 100 microCi) Radiation Safety Sodium Iodide I 131 Capsules Diagnostic is a radioactive drug and should be handled with appropriate safety measures to minimize radiation exposure to the patient and healthcare worker [see Warnings and Precautions ]
  • Use waterproof gloves during the entire handling and administration procedure
  • Maintain adequate shielding during the life of the product
  • Open the capsule-containing vial in a well ventilated hood to avoid exposure to trace levels of volatile I-131 which may be present
  • Measure patient dose by a suitable radioactivity calibration system immediately prior to administration
  • Recommended Dosage and Administration Instructions Administer Sodium Iodide I 131 Capsules Diagnostic orally prior to scanning
  • The recommended dose of Sodium Iodide I 131 Capsules Diagnostic for an adult patient is the following: Thyroid Function: 0.185 to 1.1 megabecquerels (MBq) [5 to 30 microcuries (microCi)]
  • Administer 24 hours before uptake measurement
  • Thyroid Imaging (Scintigraphy): 1.85 to 3.70 MBq (50 to 100 microCi)
  • Administer 16 -24 hours before imaging. …
Fortalezas en las que viene

Capsules: Each capsule contains 3.70 MBq (100 microCi) at time of calibration. Half of each capsule is white, while the other half is either pink, yellow, orange, grey or green according to the manufactured lot. …

Infancia
  • Safety and efficacy
  • In pediatric patients have not been established
  • Published reports suggest that the thyroid gland of pediatric patients is more sensitive to the adverse effects of sodium iodide I 131 (e.g., increased risk of radiation absorption)
Older adults

Clinical experience has not identified differences in safety or effectiveness in geriatric patients compared to younger patients. However, elderly patients are more likely to have decreased renal function and radiation exposure is greater in patients with impaired renal function [see Use in Specific Populations ( 8.6 ) , Clinical Pharmacology ( 12.3 ) ].

While you are taking it
  • Administration Instructions Advise patients to hydrate before and after administration of Sodium Iodide I 131 Capsules Diagnostic and void frequently to ensure rapid excretion [see Dosage and Administration ]
  • Advise patients to fast at least 2 hours before and 2 hours after administration to ensure absorption [see Dosage and Administration ]
  • Advise patients to maintain a low-iodine diet two weeks prior to radioiodine administration and continue for several days during the uptake or imaging process [See Dosage and Administration and Drug Interactions ]. …
Talk to a doctor first if
  • Sodium Iodide I 131 Capsules Diagnostic is contraindicated in pregnancy [see Warnings and Precautions , Use in Specific Populations ]
  • Pregnancy
Medicines it may not mix with

Certain drugs and iodine-containing foods interfere with the accumulation of radioiodide by the thyroid. Review the patients history, current medications, and recent diagnostic tests prior to the administration of Sodium Iodide I-131 Capsules Diagnostic. Advise patients to maintain a low-iodine diet two weeks prior to radioiodine administration and continue for several days during the uptake or imaging process and to discontinue the following products before they undergo the procedure as shown in Table 3: Table 3 Pharmaceuticals/OTCs/Agents Blocking Radioiodine Uptake ​Products Recommended duration of withdrawal Thionamide medications (e.g., propylthiouracil, methimazole carbimazole) 3 days …

Warnings

Fetal Toxicity – I 131 can cause severe and irreversible hypothyroidism in the neonate. Verify absence of pregnancy before administering the product. ( 4 , 5.1 , 8.1, 8.3 ) Radiation Risk – I 131 contributes to patients’s long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure. ( 5.2 ) 5.1 Fetal Toxicity Sodium Iodide I 131 Capsules Diagnostic is contraindicated in pregnancy because sodium iodide I 131 crosses the placenta and can cause severe and irreversible hypothyroidism in the neonate. …

Posibles efectos secundarios

The following adverse reaction has been described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions ( 5.4 ) ] The following adverse reactions have been identified during post-approval use from Sodium Iodide I 131 Capsules Diagnostic. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary Sodium Iodide I 131 Capsules Diagnostic is contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible. Data from the published literature describe reports of neonatal thyroid abnormalities after fetal exposure, including agenesis of the thyroid and hypothyroidism (see Clinical Considerations, Data ). …

If you take too much

In the event of an overdosage of Sodium Iodide I 131 Capsules Diagnostic, monitor for thyroid suppression and consider administering a thyroid blocking agent (e.g. potassium iodide (KI) or perchlorate). Promote frequent voiding and encourage patients to maintain hydration to minimize radiation exposure.

Si olvidas una dosis

Tómala en cuanto te acuerdes, salvo que falte poco para la siguiente. En ese caso, sáltate la olvidada. Nunca tomes dos dosis a la vez para compensar. Revisa tu prospecto, porque algunos medicamentos son distintos.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2020-08-25.

Label for diagnostic instrument, the active ingredient registered with NAFDAC.

Check your pack of Cobas Pulse

Add the expiry date on your pack for a full Trust Score.

O haz fotos de la caja
Te quedan 3 verificaciones gratis hoy Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Cobas Pulse

What is in Cobas Pulse?

Cobas Pulse contains Diagnostic Instrument (NA), as na, according to its NAFDAC registration record.

Is Cobas Pulse registered with NAFDAC?

Yes. Cobas Pulse is listed on the NAFDAC register under registration number A3-101048, and its registration is active as of 3 November 2026.

Has Cobas Pulse been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Cobas Pulse in our automatically synced alert list.

How can I check that my pack of Cobas Pulse is genuine?

Run a free authenticity scan with the NAFDAC number A3-101048, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Cobas Pulse?

Follow your prescription or the leaflet in your pack. The official label says: Use careful handling with appropriate safety measures to minimize radiation exposure to patients and healthcare workers. ( 2.1 , 5.2 ) Follow suitable radioactivity calibration prior to administration. ( 2.1 ) In an adult patient, recommended doses are ( 2.2 ): Thyroid Function: 0.185 to 1.1 megabecquerels (MBq) [5 to 30 microcuries (microCi)] Thyroid Imaging: 1.85 to 3.70 MBq …

What is Cobas Pulse used for?

Sodium Iodide I 131 Capsules Diagnostic is indicated for use in adults for: Assessment of thyroid function using radioactive iodine (RAI) uptake test Imaging the thyroid (scintigraphy) Sodium Iodide I 131 Capsules Diagnostic is a radioactive diagnostic agent indicated for the assessment of thyroid function and for thyroid imaging. (Summarised from the official U.S. FDA label for diagnostic instrument. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Cobas Pulse? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.